Antiplatelet Drug, Intracranial Arteriosclerosis, Ischemic Stroke, Secondary Prevention
Conditions
Brief summary
The goal of this clinical trial is to learn about efficacy and safety of dual antiplatelet therapy in ischemic stroke with intracranial artery stenosis. The main question it aims to answer are: whether aspirin combined with clopidogrel for 3 month is better than 1 months for patients with non-cardiogenic cerebral infarction with intracranial artery stenosis. Participants will get dual antiplatelet therapy (aspirin plus clopidogrel) for 1 month or 3 months within 7 days of the first stroke. Researchers will compare experimental group (3 months dual antiplatelet therapy) with comparison group (1 month dual antiplatelet therapy), to see if experimental group would reduce stroke recurrence or mortality, and increase bleeding and other adverse prognosis.
Interventions
DRUGclopidogrel for 90 days combined with aspirin for 90 days
Clopidogrel 300mg on the first day, then 75mg/day for 90 consecutive days; Aspirin 100mg/day for 90 days
DRUGclopidogrel for 30 days combined with aspirin for 90 days
Clopidogrel 300mg on the first day, then 75mg/ day for 30 consecutive days; Aspirin 100mg/ day for 90 days
Sponsors
Sichuan Provincial People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age 40 \ 80 years old; 2. Patients diagnosed as non-cardiogenic cerebral infarction according to the WHO definition of stroke, with MRA/CTA/DSA confirmed intracranial artery stenosis ≥50% (intracranial carotid artery, M1 and proximal M2 segment of middle cerebral artery, A1 and A2 segment of anterior cerebral artery, P1 and P2 segment of posterior cerebral artery, intracranial vertebral artery and basilar artery); 3. First stroke onset within 7 days; 4. NIHSS score ≤5; 5. Patients or family members sign informed consent forms;
Exclusion criteria
1. Patients receiving thrombolysis or endovascular therapy; 2. Patients with recurrent stroke; 3. Patients has undergone major surgery or major trauma within the past 30 days; 4. History of gastrointestinal bleeding, active peptic ulcer, intracranial hemorrhage or other hemorrhagic diseases; 5. Contraindications or intolerances to the use of antiplatelet therapeutics; 6. Platelet count \<100\*109/L, hemoglobin\<110g/L; 7. Patients with severe organ insufficiency or other serious disease (e.g., severe cardiopulmonary failure, advanced tumor, severe dementia); 8. Patients intolerant to MRI scan are replaced by CT or DSA; 9. poor compliance, unable to meet the requirements of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3-month major ischemic events and major bleeding events | 3-month | Including any of the following: Cardiovascular and cerebrovascular mortality, Incidence of stroke (including ischemic and hemorrhagic), Incidence of myocardial infarction, bleeding events classified by BARC (Bleeding Academic Research Consortium) criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| disability | 3-month | mRS(Modified Rankin Scale)\>2 |
| Cardiovascular or cerebrovascular mortality | 3-month | mortality of Cardiovascular or cerebrovascular disease |
Countries
China
Contacts
Primary ContactJie Yang, doctor
Backup ContactJiang Guo, doctor
Outcome results
None listed